Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy BioCryst Pharmaceuticals stock | $15.77
Learn how to easily invest in BioCryst Pharmaceuticals stock.
BioCryst Pharmaceuticals, Inc is a biotechnology business based in the US. BioCryst Pharmaceuticals shares (BCRX) are listed on the NASDAQ and all prices are listed in US Dollars. BioCryst Pharmaceuticals employs 246 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in BioCryst Pharmaceuticals
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – BCRX – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
BioCryst Pharmaceuticals stock price (NASDAQ: BCRX)Use our graph to track the performance of BCRX stocks over time.
BioCryst Pharmaceuticals shares at a glance
|Latest market close||$15.77|
|52-week range||$3.30 - $17.74|
|50-day moving average||$16.29|
|200-day moving average||$12.39|
|Wall St. target price||$18.11|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.15|
Buy BioCryst Pharmaceuticals shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy BioCryst Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
BioCryst Pharmaceuticals price performance over time
|1 week (2021-07-18)||N/A|
|1 month (2021-06-29)||1.81%|
|3 months (2021-04-29)||30.12%|
|6 months (2021-01-25)||N/A|
|1 year (2020-07-25)||N/A|
|2 years (2019-07-25)||N/A|
|3 years (2018-07-25)||N/A|
|5 years (2016-07-25)||N/A|
BioCryst Pharmaceuticals financials
|Revenue TTM||$32 million|
|Gross profit TTM||$-106,828,000|
|Return on assets TTM||-56.36%|
|Return on equity TTM||-1925.37%|
|Market capitalisation||$3 billion|
TTM: trailing 12 months
Shorting BioCryst Pharmaceuticals shares
There are currently 19.2 million BioCryst Pharmaceuticals shares held short by investors – that's known as BioCryst Pharmaceuticals's "short interest". This figure is 1.9% down from 19.5 million last month.
There are a few different ways that this level of interest in shorting BioCryst Pharmaceuticals shares can be evaluated.
BioCryst Pharmaceuticals's "short interest ratio" (SIR)
BioCryst Pharmaceuticals's "short interest ratio" (SIR) is the quantity of BioCryst Pharmaceuticals shares currently shorted divided by the average quantity of BioCryst Pharmaceuticals shares traded daily (recently around 3.6 million). BioCryst Pharmaceuticals's SIR currently stands at 5.34. In other words for every 100,000 BioCryst Pharmaceuticals shares traded daily on the market, roughly 5340 shares are currently held short.
However BioCryst Pharmaceuticals's short interest can also be evaluated against the total number of BioCryst Pharmaceuticals shares, or, against the total number of tradable BioCryst Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BioCryst Pharmaceuticals's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 BioCryst Pharmaceuticals shares in existence, roughly 110 shares are currently held short) or 0.1172% of the tradable shares (for every 100,000 tradable BioCryst Pharmaceuticals shares, roughly 117 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against BioCryst Pharmaceuticals.
Find out more about how you can short BioCryst Pharmaceuticals stock.
BioCryst Pharmaceuticals share dividends
We're not expecting BioCryst Pharmaceuticals to pay a dividend over the next 12 months.
BioCryst Pharmaceuticals share price volatility
Over the last 12 months, BioCryst Pharmaceuticals's shares have ranged in value from as little as $3.3 up to $17.74. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioCryst Pharmaceuticals's is 2.6159. This would suggest that BioCryst Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.
BioCryst Pharmaceuticals overview
BioCryst Pharmaceuticals, Inc. , a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase I clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. BioCryst Pharmaceuticals, Inc. has collaborations and in-license relationships with the Torii Pharmaceutical Co. , Ltd.
Stocks similar to BioCryst Pharmaceuticals
BioCryst Pharmaceuticals in the news
BioCryst Appoints Vincent Milano to Board of Directors
Unusually active option classes on open July 28th
BioCryst Appoints Vincent Milano to Board of Directors
Frequently asked questionsWhat percentage of BioCryst Pharmaceuticals is owned by insiders or institutions?
Currently 0.866% of BioCryst Pharmaceuticals shares are held by insiders and 61.218% by institutions. How many people work for BioCryst Pharmaceuticals?
Latest data suggests 246 work at BioCryst Pharmaceuticals. When does the fiscal year end for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals's fiscal year ends in December. Where is BioCryst Pharmaceuticals based?
BioCryst Pharmaceuticals's address is: 4505 Emperor Boulevard, Durham, NC, United States, 27703 What is BioCryst Pharmaceuticals's ISIN number?
BioCryst Pharmaceuticals's international securities identification number is: US09058V1035 What is BioCryst Pharmaceuticals's CUSIP number?
BioCryst Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 09058V103
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert